Currently, employers choose health plans based on administrative costs and provider discounts, but they need to start engaging around value-based reimbursement, said Michael Thompson, president and chief executive officer of the National Alliance of Healthcare Purchaser Coalitions.
Currently, employers choose health plans based on administrative costs and provider discounts, but they need to start engaging around value-based reimbursement, said Michael Thompson, president and chief executive officer of the National Alliance of Healthcare Purchaser Coalitions.
Transcript
How can mandatory bundled payments reduce the cost of care for employers?
You know, today we’re in a system that rewards volume rather than value, and the advantage of a bundled payment—type approach is that it essentially is designed in a manner to pay for the care that’s needed to execute on an episode of care. And by including appropriate incentives and warranties around quality in those payments, you actually reward value delivered by the providers themselves.
In some instances, we’ve actually found where the fee-for-service system does not reward a high-performing system. For example, in the area of substance use disorder. That’s an area where we’re looking at new models of reimbursement that are more conducive to the initial treatment and the ongoing support of people with those conditions.
From your experience, what are the main things purchasers consider when they shop for health plans?
You know, how purchasers select health plans today and how we ultimately need to select health plans can be 2 different things. Today, it’s largely driven on 2 factors: their administrative costs and the discounts that they’re receiving from providers. When the evaluation is done by consulting firms, those tend to be the dominant factors in the performance.
I think increasingly we need to get to working with health plans that are more progressive in how they are engaging with providers around value-based reimbursement, around the support with consumers, and the downstream impact on outcomes and value. That’s a little more difficult evaluation, but ultimately, I think that’s how health plans can distinguish themselves from each other.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide
June 4th 2025Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.
Read More